It will be interesting to see how the much the PPS reacts to positive news. Hopefully, we will have less motivated sellers on the way up as we reach clinical milestones.
I want our management team to finalize one last finance arrangement to progress us through LymPro commercialization (minimizing the downside risk). Also, I think their will be a surprise collaboration on the MANF side (to expedite commercialization for the MANF Orphan indications).
Better times ahead....the longs have earned greater returns on our investment. GLTA!!!